Swedish Orphan Biovitrum (SWTUY) Downgraded by Zacks Investment Research

Zacks Investment Research downgraded shares of Swedish Orphan Biovitrum (OTCMKTS:SWTUY) from a buy rating to a hold rating in a research report report published on Thursday.

According to Zacks, “Swedish Orphan Biovitrum AB is a biopharmaceutical company which develops and makes drugs for patients with rare diseases. Its product portfolio primarily includes Kineret within the inflammation therapeutic area, Orfadin, Ammonaps and Ammonul within the genetics and metabolic therapeutic which are in clinical trial stage. Swedish Orphan Biovitrum AB is headquartered in Stockholm, Sweden. “

How to Become a New Pot Stock Millionaire

Shares of OTCMKTS SWTUY opened at $18.50 on Thursday. Swedish Orphan Biovitrum has a twelve month low of $12.55 and a twelve month high of $18.50. The stock has a market capitalization of $5,041.39, a price-to-earnings ratio of 52.86, a price-to-earnings-growth ratio of 0.84 and a beta of 1.52.

ILLEGAL ACTIVITY WARNING: This news story was reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://www.thelincolnianonline.com/2018/04/16/swedish-orphan-biovitrum-swtuy-downgraded-by-zacks-investment-research.html.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB (publ), an integrated biopharmaceutical company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetics and metabolism diseases primarily in Sweden and internationally. Its core products include Kineret for the treatment of rheumatoid arthritis and neonatal-onset multisystem inflammatory disease; Orfadin for the treatment of hereditary tyrosinaemia type 1 genetic disorder; and Xiapex for the treatment of Dupuytren's contracture and Peyronie's disease.

Get a free copy of the Zacks research report on Swedish Orphan Biovitrum (SWTUY)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Swedish Orphan Biovitrum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Swedish Orphan Biovitrum and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply